For Majeed syndrome, there is evidence that it is an IL-1β-mediated disease, since bone inflammation and serum inflammation markers improve in response to IL-1β blockade, while TNFα blockers have almost no effect [35]. This evidence concerns the gene IL1B and Majeed syndrome.